Evidence map›Paper›PMID 41695615›Full record

ReviewMolecular neurodegeneration advances2026

Spilling the T: T cells in tauopathy mechanisms, disease progression, and therapeutic horizons.

Megan E Bosch, Jason D Ulrich

Abstract readReview
In one paragraph

Review in Molecular neurodegeneration advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Megan E BoschDepartment of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, 4370 Duncan Street, St. Louis, MO 63110 USA.
Jason D UlrichDepartment of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, 4370 Duncan Street, St. Louis, MO 63110 USA.

Funding

Role of T cells in tau-mediated neurodegenerationR01AG085374 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN, Jason D Ulrich · 2024 to 2026
$2.2M
NIA NIH HHS R01 AG085374
6 · The paper itself

Abstract

Primary and secondary tauopathies are major causes of dementia characterized by the abnormal accumulation of microtubule-associated protein tau. Tau aggregation initiates neuronal dysfunction and death, while despite the distinct and pathological features of individual tauopathies, accumulating evidence shows that these disorders converge on shared mechanistic pathways marked by chronic inflammation and progressive neuronal loss. The innate immune response has been extensively studied in this context, yet the contribution of the adaptive immune system, particularly T cells, has only recently gained attention. In this review, we examine emerging evidence for adaptive immune involvement in tauopathies, including mechanisms that drive T cell activation and infiltration into the central nervous system, their effector functions once within the parenchyma, and how these responses interact with innate immune signaling. We also highlight potential therapeutic strategies aimed at modulating adaptive immunity in primary and secondary tauopathies. Current findings suggest that tau accumulation and glial-driven neuroinflammation creates an environment that promotes the activation and recruitment of effector T cells into the tauopathy brain. Importantly, blocking or reshaping the T cell responses shows promise for mitigating neurodegeneration, highlighting the adaptive immune system as a potential therapeutic target.

Indexed as

Adaptive immune responseTauopathiesT cells

Identifiers

PMID41695615
PMCPMC12901281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.